COL18A1 and neoplasm: In an orthotopic ovarian cancer mouse model, the combination of carboplatin, a standard-of-care chemotherapy in ovarian cancer, and rAAV-mediated delivery of the anti-angiogenic mutant endostatin (rAAV-P125A-endostatin) resulted in a significant decrease in tumor burden and an increase in survival compared to the single agents alone or the untreated group [75].